Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced it will deliver
eight presentations showcasing its mRNA cell engineering platform
at the American Society of Gene & Cell Therapy (ASGCT) Annual
Meeting, taking place May 16-20, 2023 at the Los Angeles Convention
Center.
Susan McClatchey, Vice President, Quality at Eterna
Therapeutics, will participate in a fireside chat, hosted by
Citeline, about the manufacturing of gene therapies.
Title: Overcoming the Manufacturing and
Regulatory Challenges for Gene TherapiesDate/Time:
May 17, Doors open 6:00 PM PTSpeaker: Susan
McClatchey, Vice President, Quality at Eterna
TherapeuticsLocation: Grammy Museum, 800 W Olympic
Blvd, Los Angeles, CA 90015
Details of Eterna’s poster presentations are below, including
several posters presented by or in conjunction with Eterna’s
discovery partner, Factor Bioscience.
Title: Rational Design of Multivalent Ionizable
Lipid Delivery Systems for mRNA Delivery to Blood
CellsAbstract & Poster Board Number:
563Presenter: Elizabeth Belcher, Research
Associate I at Eterna TherapeuticsSession &
Location: Wednesday Poster
Session, West Hall
ADate/Time: May 17, 12:00-2:00 PM PT
Title: A Scalable, iPS Cell Derived Lymphocyte
and Myeloid Multi-Cell-Type Therapeutic Platform for Enhanced Tumor
Cell Killing*Abstract & Poster Board Number:
616Presenter: Abigail J. Blatchford, Associate
Scientist at Factor BioscienceSession &
Location: Wednesday Poster Session, West Hall
ADate/Time: May 17, 12:00-2:00 PM PT
Title: Chemically Modified Single-Stranded DNA
Donors Enable Efficient mRNA Gene Editing-Mediated Knock-In in
Human iPS Cells*Abstract & Poster Board
Number: 1065Presenter: Claire Aibel,
Associate Scientist at Factor BioscienceSession &
Location: Thursday Poster Session, West Hall
ADate/Time: May 18, 12:00-2:00 PM PT
Title: Efficient Transgene Knock-In in Human
iPS Cells Combined with Small Molecule-Mediated “On-Switch” Yields
Clonal Populations of Engineered Tissue-Specific
Cells*Abstract & Poster Board Number:
1103Presenter: Taeyun Kim, Associate Scientist at
Factor BioscienceSession & Location: Thursday
Poster Session, West Hall ADate/Time: May 18,
12:00-2:00 PM PT
Title: Novel Ionizable Lipids Derived from
2-Hydroxypropylamine and Spermine for mRNA-LNP
Delivery*Abstract & Poster Board Number:
1262Presenter: Ariadna Lubinus, Associate
Scientist at Factor BioscienceSession &
Location: Friday Poster Session, West Hall
ADate/Time: May 19, 12:00-2:00 PM PT
Title: Directed Differentiation of Gene Edited
iPSCs by Small-Molecule Inhibition of a Transgene-Encoded
ProteinAbstract & Poster Board Number:
1314Presenter: Raven Dance Klee, Research
Associate II at Eterna TherapeuticsSession &
Location: Friday Poster Session, West Hall
ADate/Time: May 19, 12:00-2:00 PM PT
Title: Gene Editing Proteins with Nickase
Functionality Enable Scarless Targeted Gene Insertion in Primary
Human CellsAbstract & Poster Board Number:
1516Presenter: Elizabeth Belcher, Research
Associate I at Eterna TherapeuticsSession &
Location: Friday Poster Session, West Hall
ADate/Time: May 19, 12:00-2:00 PM PT
Title: mRNA Cell Engineering Enables Rapid
Prototyping of Macrophage Gene-Editing Strategies for Cancer
Immunotherapy Applications*Abstract & Poster Board
Number: 1563Presenter: Ian Hay, Associate
Scientist at Factor BioscienceSession &
Location: Friday Poster Session, West Hall
ADate/Time: May 19, 12:00-2:00 PM PT
Abstracts are available on the ASGCT Annual Meeting website
here.
*Research conducted and presented by discovery partner Factor
Bioscience.
About Eterna Therapeutics Inc.Eterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 100 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please
visit www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on mRNA, iPS cell and gene editing technologies; (ii)
Eterna’s ability to successfully, cost-effectively and efficiently
develop its technology and products; (iii) Eterna’s ability to
successfully commence clinical trials of any products on a timely
basis or at all; (iv) Eterna’s ability to successfully fund and
manage the growth of its development activities; and (v) Eterna ’s
ability to obtain regulatory approvals of its products for
commercialization. You should not rely upon forward-looking
statements as predictions of future events. The forward-looking
statements made in this communication speak only as of the date on
which they were made, and Eterna does not undertake any obligation
to update the forward-looking statements contained herein to
reflect events that occur or circumstances that exist after the
date hereof, except as required by applicable law. Factors that may
cause Eterna’s actual results to differ from those expressed or
implied in forward-looking statements contained in this press
release are more fully disclosed in Eterna’s periodic public
filings with the U.S. Securities and Exchange Commission,
particularly under the heading “Risk Factors” in Eterna’s Annual
Report on Form 10-K for the year ended December 31, 2022, as well
as under similar headings in Eterna’s subsequently filed Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:EternaPR@westwicke.com
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024